The original patent for Thiotepa has long since expired. Patents for drugs like Thiotepa, which was first synthesized in the 1950s, are typically granted for a term of 20 years from the filing date [1].
When was Thiotepa first approved?
Thiotepa was first approved by the U.S. Food and Drug Administration (FDA) in 1961 [2]. This early approval date indicates that the initial patent protection would have ended decades ago.
What is Thiotepa used for?
Thiotepa is an alkylating agent used in the treatment of certain types of cancer, including breast cancer, ovarian cancer, and lymphomas. It is also used in high-dose chemotherapy regimens, often as part of a stem cell transplant, to manage specific hematologic malignancies [3][4].
Are there any current patents related to Thiotepa?
While the original composition of matter patent has expired, there may be patents covering specific formulations, manufacturing processes, or new uses of Thiotepa. Companies can seek new patents for such innovations, extending market exclusivity for those particular aspects [1]. DrugPatentWatch.com tracks patent and exclusivity information for pharmaceutical products.
Who manufactures Thiotepa?
Several companies have been involved in the manufacturing and marketing of Thiotepa over the years. Currently, Novation and Teva Pharmaceuticals are listed as manufacturers or distributors [2].